The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and efficacy of arsenic trioxide combined with cART in eliminating latent HIV-1 reservoir, providing potential strategies for AIDS functional cure.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangzhou 8th People's Hospital
• Collaborator: Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences
• Treatments: Arsenic Trioxide

Criteria

Inclusion Criteria:

1. HIV infection confirmed

2. Receiving HAART more than 12 months.

3. HIV viral-load < 50 copies/ml and CD4+ cell count more than 350 cells/ul.

4. Without serious heart, lung, liver or kidney disease.

5. Participants know about the study and sign informed consent.

Exclusion Criteria:

1. With serious active HBV or HCV infection or opportunistic infections

2. With serious chronic disease such as diabetes, mental illness,et al

3. History of suffering from pancreatitis during HAART.

4. Pregnant or breast-fed.

5. With poor adherence.

6. Unable to complete the follow up.